Cangrelor (tetrasodium)

163706-36-3

864.29

H2O : 250 mg/mL (289.25 mM; Need ultrasonic)

GPCR/G Protein

Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist^[1][2]. In Vitro: Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist^[1].
Cangrelor tetrasodium has pK_b of 8.6-9.2 for hP2Y12 receptor^[3]. In Vivo: Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice^[2].